Marco Donia
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Marco Donia
May 25, 2024, 10:05 |
Insight
Marco Donia: The Role of PD-L1 Assessment in Dual Checkpoint Inhibition for Melanoma
Marco Donia, Clinical Research Associate Professor at the University of Copenhagen, shared on LinkedIn: "The…
May 22, 2024, 09:36 |
Blog
Marco Donia: Does participation in Cancer Clinical Trials improve survival outcomes on its own?
Marco Donia, made the following post on LinkedIn: "Does participation in Cancer Clinical Trials improve survival…
May 22, 2024, 04:25 |
Blog
Timothée Olivier: One of the most important and practice-changing piece this year
Timothée Olivier, Medical Oncologist at HUG – Geneva University Hospitals, shared a post on X…
May 12, 2024, 17:41 |
Insight
Marco Donia: Circadian rhythm, tumor infiltration of CD8+ T cells, and cancer immunotherapy
Marco Donia, Clinical Research Associate Professor at the University of Copenhagen, shared on LinkedIn: “Circadian…
May 6, 2024, 07:29 |
Insight
Center for Cancer Immune Therapy - Molecular patterns of resistance to immune checkpoint blockade in melanoma
Center for Cancer Immune Therapy shared on LinkedIn: "Molecular patterns of resistance to immune checkpoint…
May 2, 2024, 13:23 |
Insight
Marco Donia: Welcoming the Era of Gene Editing in Medicine
Marco Donia, Clinical Research Associate Professor at the University of Copenhagen, shared on LinkedIn: "Autologous…
Apr 20, 2024, 07:47 |
Drugs
Paper summary by Marco Donia
Marco Donia, Clinical Research Associate Professor at the University of Copenhagen, shared a post on…
Apr 11, 2024, 15:57 |
Insight
Marco Donia: Therapeutic Cancer Vaccines - update in Melanoma
Marco Donia, Clinical Research Associate Professor at the University of Copenhagen, shared a post on…
Apr 9, 2024, 05:22 |
Blog
Marco Donia: Must Read: 50 years of Advances in Cancer Research
Marco Donia, Clinical Research Associate Professor at the University of Copenhagen, shared a post on…
Mar 22, 2024, 18:47 |
Blog
Alessandra Fontecedro: The first Swiss Oncology Summer School
Alessandra Fontecedro, Head Medical Oncology at HFR Fribourg Hospital, shared on LinkedIn: "To medical students:…
Mar 1, 2024, 17:25 |
Insight
Marco Donia: The 'Influencers' of Cancer Immunotherapy do not affect immunotherapy outcomes
Marco Donia, Associate Professor at National Center for Cancer Immune Therapy, Denmark, shared on LinkedIn: "The…
Feb 19, 2024, 17:52 |
Insight
Marco Donia: Pan-cancer proteogenomics characterization of tumor immunity
Marco Donia, Associate Professor at National Center for Cancer Immune Therapy, Denmark, shared on LinkedIn: ''Pan-cancer…
Feb 10, 2024, 23:33 |
Insight
Bettina Ryll: Got to kind of love the authors
Bettina Ryll, Founder of MPNEurope, shared a post by Marco Donia, Associate Professor at National Center for…
Jan 26, 2024, 10:54 |
Insight
Marco Donia: We discuss a combined transcriptional and phenotype signature, NeoTCRPBL
Marco Donia, Associate Professor at National Center for Cancer Immune Therapy, Denmark, shared on LinkedIn: Harnessing…
Jan 9, 2024, 16:16 |
Opinion
Marco Donia: Stating your hypothesis in grant applications might be unnecessary and even harmful
Marco Donia, Associate Professor at National Center for Cancer Immune Therapy, Denmark, shared the following post…
Dec 24, 2023, 18:05 |
Insight
Marco Donia: Adjuvant Anti-PD-1 Immunotherapy for Resected Melanoma: Update December 2023
Marco Donia, Associate Professor at National Center for Cancer Immune Therapy, Denmark, shared on LinkedIn:…
Dec 18, 2023, 21:01 |
Insight
Marco Donia: The end almost no one talks about (the constant region) is actually quite important
Marco Donia, Clinical Research Associate Professor at University of Copenhagen, shared on LinkedIn: "Immunomodulatory antibodies have…
Dec 2, 2023, 17:44 |
Insight
Marco Donia: Patients undergoing immunotherapy can safely receive SBRT upon indication
Marco Donia, Clinical Research Associate Professor at University of Copenhagen, shared on LinkedIn: "Adding Stereotactic Body…
Nov 26, 2023, 17:27 |
Insight
Marco Donia: Most combinations in oncology have additive but not synergistic efficacy
Marco Donia, Clinical Research Associate Professor at University of Copenhagen, shared on LinkedIn: "Most combinations…
Oct 9, 2023, 18:57 |
Blog
Marco Donia: All (almost) you need to know about Evidence in Cancer Immunotherapy.
Marco Donia, Clinical Research Associate Professor at University of Copenhagen, shared a post on LinkedIn,…
All:
20
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube